Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GCG | P01275 | 10/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719243 | 0.97 | MEN1 (0.42) | MEN1KMT2AGCGMAPTSMN1; SMN2 | |
| SCHEMBL3401958 | 0.95 | GCG (0.41) | GCGMAPTNPC1RAB9A | |
| SCHEMBL721612 | 0.90 | MEN1 (0.40) | MEN1KMT2AGCGMAPTSMN1; SMN2 | |
| SCHEMBL718361 | 0.89 | MEN1 (0.44) | MEN1KMT2AGCGMAPTSMN1; SMN2 | |
| SCHEMBL719039 | 0.88 | MEN1 (0.42) | MEN1KMT2AGCGMAPTSMN1; SMN2 | |
| SCHEMBL720090 | 0.88 | KDM4E (0.34) | KMT2AMAPTNPC1RAB9AKDM4E | |
| SCHEMBL716647 | 0.88 | MEN1 (0.42) | MEN1KMT2AGCGMAPTSMN1; SMN2 | |
| SCHEMBL721484 | 0.86 | GCG (0.43) | GCGMAPTNPC1RAB9A | |
| SCHEMBL718026 | 0.86 | MEN1 (0.43) | MEN1KMT2AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL719411 | 0.86 | KDM4E (0.35) | KMT2AMAPTNPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MEN1 444/4885KMT2A 1298/4885GCG 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.